Principal Investigator
Byron Lam
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20230902
Clinical Trial Summary
A Phase 1 Open-Label, Single Arm Dose Escalation Study to
Evaluate the Safety and Tolerability of Intravitreally
Administered VP-001 in Participants with Confirmed PRPF31
Mutation-Associated Retinal Dystrophy
Phase
TBD
Funding Agency/Sponsor
Intramural
Disease
Other